SYS-CON MEDIA Authors: Jason Bloomberg, Elizabeth White, Zakia Bouachraoui, Andy Thurai, Liz McMillan

News Feed Item

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players

NEW YORK, May 14, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players

MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players


Acute coronary syndrome (ACS) consists of two major diseases: myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. Emergence of two pipeline biomarker tests, Thermo Scientific's copeptin, and heart-type fatty acid binding protein (H-FABP), will provide further diagnostic options to emergency physicians.

This report identifies the unmet needs in the market, provides an understanding of physician perception of ACS diagnostic cardiac biomarker testing, and future trends. Through GlobalData's analysis, it is evident that the ACS diagnostic cardiac biomarker testing market is dominated by a single player, but it is expected that pipeline tests will begin to be used in combination with this test. To successfully market new diagnostic tests, companies need to offer tests that address the current unmet needs of current ACS diagnostic cardiac biomarker tests and show advantages in combination with tests currently in the market. This report will identify the opportunities for this technology.


- Investigation of current and future market competition for ACS diagnostic cardiac biomarker testing. - Competitor assessment. - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL), including clinical biochemists, laboratory managers, emergency physicians, and cardiologists using these diagnostic tests.

Reasons to buy

- Gain a high level view of the trends shaping and driving the ACS diagnostic cardiac biomarker testing market. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 Catalyst 83 Competitive Assessment 93.1 Overview 93.2 Cardiac Troponins 103.2.1 Overview 103.2.2 Clinical Application and Utility 123.2.3 Market Penetration 173.2.4 SWOT Analysis 173.3 Creatine Kinase-MB 183.3.1 Overview 183.3.2 Clinical Application and Utility 193.3.3 Market Penetration 203.3.4 SWOT Analysis 203.4 Myoglobin 213.4.1 Overview 213.4.2 Clinical Application and Utility 223.4.3 Market Penetration 233.4.4 SWOT Analysis 233.5 Point-of-Care 243.5.1 Overview 243.5.2 Clinical Application and Utility 253.5.3 Market Penetration 283.5.4 SWOT Analysis 294 Pipeline Products 304.1 Overview 304.2 BAG3 (Biouniversia) 314.2.1 Overview 314.2.2 SWOT Analysis 314.3 CAVARISK (Cavadis) 324.3.1 Overview 324.3.2 SWOT Analysis 324.4 CardioScore (BG Medicine) 334.4.1 Overview 334.4.2 SWOT Analysis 334.5 Circulating Endothelial Cells 344.5.1 Overview 344.5.2 SWOT Analysis 354.6 Copeptin (Thermo Scientific) 364.6.1 Overview 364.6.2 SWOT Analysis 394.7 Heart-Type Fatty Acid Binding Protein 404.7.1 Overview 404.7.2 SWOT Analysis 424.8 MIRISK VP Assessment (Aviir) 434.8.1 Overview 434.8.2 SWOT Analysis 434.9 Early Emerging Tests 444.9.1 Heart Diagnostic Assay (Prevencio/University of Pittsburgh) 444.9.2 Sentinel CVD (GeneNews) 444.9.3 SomaScan Cardiovascular Assay (SomaLogic) 445 Current and Future Players 455.1 Overview 455.2 Trends in Corporate Strategy 455.3 Abbott Diagnostics 465.3.1 Overview 465.3.2 Portfolio Assessment 465.4 Alere 485.4.1 Overview 485.4.2 Portfolio Assessment 495.5 Beckman Coulter 505.5.1 Overview 505.5.2 Portfolio Assessment 515.6 bioMérieux 525.6.1 Overview 525.6.2 Portfolio Assessment 535.7 Mitsubishi Chemical Medience Corporation 545.7.1 Overview 545.7.2 Portfolio Assessment 555.8 Ortho-Clinical Diagnostics 565.8.1 Overview 565.8.2 Portfolio Assessment 575.9 Radiometer Medical 585.9.1 Overview 585.9.2 Portfolio Assessment 595.10 Randox Laboratories 605.10.1 Overview 605.10.2 Portfolio Assessment 615.11 Response Biomedical 625.11.1 Overview 625.11.2 Portfolio Assessment 635.12 Roche Diagnostics 645.12.1 Overview 645.12.2 Portfolio Assessment 645.13 Siemens Healthcare 665.13.1 Overview 665.13.2 Portfolio Assessment 675.14 Thermo Scientific 685.14.1 Overview 685.14.2 Portfolio Assessment 696 Appendix 706.1 Bibliography 706.2 Abbreviations 816.3 Research Methodology 836.3.1 Overview 836.3.2 Coverage 836.3.3 Secondary Research 836.3.4 Forecast Methodology 846.4 Primary Research 856.5 Physicians and Specialists Included in this Study 866.6 About the Authors 876.6.1 Analysts 876.6.2 Global Head of Healthcare 886.7 About MediPoint 896.8 About GlobalData 896.9 Contact Us 896.10 Disclaimer 89

List of Tables

Table 1: Product Profile – Cardiac Troponins 11Table 2: Cardiac Troponin Concentrations of Selected Current Troponin Assays 13Table 3: Cardiac Troponin Concentrations of Selected High-Sensitivity Troponin Assays 14Table 4: Cardiac Troponins SWOT Analysis 17Table 5: Product Profile – Creatine Kinase-MB 18Table 6: Creatine Kinase-MB SWOT Analysis 20Table 7: Product Profile – Myoglobin 21Table 8: Myoglobin SWOT Analysis 23Table 9: Product Profile – Point-of-Care Testing 24Table 10: Cardiac Troponin Concentrations of POC Troponin Assays 26Table 11: Point-of-Care Cardiac Panel SWOT Analysis 29Table 12: ACS Cardiac Biomarker Global Product Pipeline 30Table 13: BAG3 SWOT Analysis 31Table 14: CAVARISK SWOT Analysis 32Table 15: CardioScore SWOT Analysis 33Table 16: Circulating Endothelial Cells SWOT Analysis 35Table 17: Copeptin SWOT Analysis 39Table 18: Heart-Type Fatty Acid Binding Protein SWOT Analysis 42Table 19: MIRISK VP SWOT Analysis 43Table 20: Company Profile – Abbott Diagnostics 46Table 21: Abbott Diagnostics SWOT Analysis, 2013 47Table 22: Company Profile – Alere 48Table 23: Alere SWOT Analysis, 2013 49Table 24: Company Profile – Beckman Coulter 50Table 25: Beckman Coulter SWOT Analysis, 2013 51Table 26: Company Profile – bioMérieux 52Table 27: bioMérieux SWOT Analysis, 2013 53Table 28: Company Profile – Mitsubishi Chemical Medience Corporation 54Table 29: Mitsubishi Chemical Medience Corporation SWOT Analysis, 2013 55Table 30: Company Profile – Ortho-Clinical Diagnostics 56Table 31: Ortho-Clinical Diagnostics SWOT Analysis, 2013 57Table 32: Company Profile – Radiometer Medical 58Table 33: Radiometer Medical SWOT Analysis, 2013 59Table 34: Company Profile – Randox Laboratories 60Table 35: Randox Laboratories SWOT Analysis, 2013 61Table 36: Company Profile – Response Biomedical 62Table 37: Response Biomedical SWOT Analysis, 2013 63Table 38: Company Profile – Roche Diagnostics 64Table 39: Roche Diagnostics SWOT Analysis, 2013 65Table 40: Company Profile – Siemens Healthcare 66Table 41: Siemens Healthcare SWOT Analysis, 2013 67Table 42: Company Profile – Thermo Scientific 68Table 43: Thermo Scientific SWOT Analysis, 2013 69

List of Figures

Figure 1: Major Market Share by Test Type for ACS In Vitro Diagnostic Testing Reagents, 2012 9

Companies mentioned

Abbott Diagnostics


Beckman Coulter


Mitsubishi Chemical Medience Corporation

Ortho-Clinical Diagnostics

Radiometer Medical

Randox Laboratories

Response Biomedical

Roche Diagnostics

Siemens Healthcare

Thermo Scientific

To order this report:Diagnostics Industry: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players


Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
While the focus and objectives of IoT initiatives are many and diverse, they all share a few common attributes, and one of those is the network. Commonly, that network includes the Internet, over which there isn't any real control for performance and availability. Or is there? The current state of the art for Big Data analytics, as applied to network telemetry, offers new opportunities for improving and assuring operational integrity. In his session at @ThingsExpo, Jim Frey, Vice President of S...
"We were founded in 2003 and the way we were founded was about good backup and good disaster recovery for our clients, and for the last 20 years we've been pretty consistent with that," noted Marc Malafronte, Territory Manager at StorageCraft, in this interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settl...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In their Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, and Mark Lav...
@CloudEXPO and @ExpoDX, two of the most influential technology events in the world, have hosted hundreds of sponsors and exhibitors since our launch 10 years ago. @CloudEXPO and @ExpoDX New York and Silicon Valley provide a full year of face-to-face marketing opportunities for your company. Each sponsorship and exhibit package comes with pre and post-show marketing programs. By sponsoring and exhibiting in New York and Silicon Valley, you reach a full complement of decision makers and buyers in ...
According to the IDC InfoBrief, Sponsored by Nutanix, “Surviving and Thriving in a Multi-cloud World,” multicloud deployments are now the norm for enterprise organizations – less than 30% of customers report using single cloud environments. Most customers leverage different cloud platforms across multiple service providers. The interoperability of data and applications between these varied cloud environments is growing in importance and yet access to hybrid cloud capabilities where a single appl...
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In today's always-on world, customer expectations have changed. Competitive differentiation is delivered through rapid software innovations, the ability to respond to issues quickly and by releasing high-quality code with minimal interruptions. DevOps isn't some far off goal; it's methodologies and practices are a response to this demand. The demand to go faster. The demand for more uptime. The demand to innovate. In this keynote, we will cover the Nutanix Developer Stack. Built from the foundat...
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Sold by Nutanix, Nutanix Mine with Veeam can be deployed in minutes and simplifies the full lifecycle of data backup operations, including on-going management, scaling and troubleshooting. The offering combines highly-efficient storage working in concert with Veeam Backup and Replication, helping customers achieve comprehensive data protection for all their workloads — virtual, physical and private cloud —to meet increasing business demands for uptime and productivity.
"Cloud computing is certainly changing how people consume storage, how they use it, and what they use it for. It's also making people rethink how they architect their environment," stated Brad Winett, Senior Technologist for DDN Storage, in this interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...